F-1/A: Haoxi Health Technology Eyes $12 Million in Unit Offering Amid Regulatory Scrutiny

Haoxi Health Technology plans a unit offering to raise capital while navigating complex PRC regulatory requirements.

Summary

• Haoxi Health Technology Limited, a Cayman Islands-based holding company with operations in China, is planning a firm commitment offering of 4,000,000 units, with an option for underwriters to purchase an additional 600,000 units.
• Each unit consists of one Class A Ordinary Share (or a pre-funded warrant), one Series A warrant, and one Series B warrant, priced at $3.00 per unit.
• The company estimates net proceeds of approximately $10.95 million, intending to use the funds for working capital, acquisitions, and improving internal controls.
• The offering is subject to complex regulatory requirements in China, including filing procedures with the CSRC under the Overseas Listing Trial Measures.
• The company faces risks associated with its operations in China, including regulatory uncertainties, potential interventions by the PRC government, and difficulties in enforcing legal judgments.
• The company's auditor is subject to PCAOB inspections, but uncertainties remain regarding potential future restrictions.
• The company is considered an emerging growth company and a controlled company under Nasdaq rules, which may affect investor protections.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative factors. The company has experienced revenue growth, but faces regulatory risks and operational challenges. The sentiment is neutral.

Positives

• The company has experienced significant revenue growth in recent periods.
• The company has a management team with experience in the healthcare marketing industry.
• The company has developed its own data analysis software, Bidding Compass.
• The company has established relationships with mainstream online advertising platforms in China.

Negatives

• The company is subject to complex and evolving regulatory requirements in China.
• The company may face difficulties in enforcing legal judgments against the company or its management in China.
• The company is dependent on a single major supplier, Ocean Engine.
• The company may experience net cash outflow from operating activities.
• The company has significantly unstable operating revenue.
• The company is exposed to concentration risk, due to its reliance on its major supplier, Ocean Engine.
• The company's plan to invest in research and development (R&D) of Bidding Compass, may fail to result in a satisfactory return, or any return.
• There is no public market for the Units or the Warrants.
• You will experience immediate and substantial dilution in the net tangible book value of Class A Ordinary Shares purchased.

Risks

• Changes in PRC political and economic policies could adversely affect the company's business.
• Uncertainties exist regarding the interpretation and enforcement of PRC laws and regulations.
• The PRC government may intervene or influence the company's operations.
• The company may be treated as a resident enterprise for PRC tax purposes.
• The company may need dividends and other distributions on equity paid by Haoxi Beijing to satisfy our liquidity requirements and any limitation on the ability of Haoxi Beijing to transfer cash out of China and/or make remittances to pay dividends to us could limit our ability to access cash generated by the operations of Haoxi Beijing.
• If advertisers stop purchasing online marketing services from the operating entity or decrease the amount they are willing to spend on marketing campaigns and promotional activities, or if the operating entity is unable to establish and maintain new relationships with advertisers, its business, financial condition, and results of operations could be materially adversely affected.
• If the operating entity fails to maintain its relationships with its media partners, its business, results of operations, financial condition and business prospects could be materially and adversely affected.
• As the operating entity continues to strive for business growth, we may continue to experience net cash outflow from operating activities, and we cannot assure you that we can maintain sufficient net cash inflows from operating activities.
• The limited operating history of the operating entity in the rapidly evolving industry makes it difficult to accurately forecast its future operating results and evaluate its business prospects.
• Certain customers contributed to a significant percentage of our total revenue during the fiscal years 2023 and 2022, and losing one or more of them could have a material adverse impact on our financial performance and business prospects.
• We have significantly unstable operating revenue, anticipate increases in our operating expenses in the future, and may not achieve or sustain profitability on a consistent basis. If we cannot achieve and sustain profitability, our business, financial condition, and operating results may be adversely affected.
• Pandemics, epidemics and other outbreaks, natural disasters, terrorist activities, and political unrest could disrupt the PRC operating entities delivery and operations, which could materially and adversely affect their business, financial condition, and results of operations.
• The operating entitys business is geographically concentrated, which subjects it to greater risks from changes in local or regional conditions.
• The operating entity is exposed to concentration risk, due to its reliance on its major supplier, Ocean Engine. If the operating entitys relationship with Ocean Engine deteriorates, or its unable to renew its agreement with Ocean Engine on substantially similar terms, our financial performance, results of operation and ongoing growth could be adversely affected.
• The operating entitys plan to invest in research and development (R&D) of Bidding Compass, may fail to result in a satisfactory return, or any return.
• There is no public market for the Units or the Warrants.
• The Warrants in this offering are speculative in nature.
• Holders of the Warrants will not have rights of holders of our Class A Ordinary Shares until such Warrants are exercised.
• Certain recent initial public offerings of companies with public floats comparable to the anticipated public float of us have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may make it difficult for prospective investors to assess the value of our Class A Ordinary Shares.
• You will experience immediate and substantial dilution in the net tangible book value of Class A Ordinary Shares purchased.
• The dual class structure of our ordinary shares has the effect of concentrating voting control with our CEO, and his interests may not be aligned with the interests of our other shareholders.
• The dual-class structure of our ordinary shares may adversely affect the trading market for our Class A Ordinary Shares.
• Since we are a controlled company within the meaning of the Nasdaq listing rules, we may follow certain exemptions from certain corporate governance requirements that could adversely affect our public shareholders.
• Substantial future sales of our Class A Ordinary Shares or the anticipation of future sales of our Class A Ordinary Shares in the public market could cause the price of our Class A Ordinary Shares to decline.
• We do not intend to pay dividends for the foreseeable future.
• If we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and we would incur significant additional legal, accounting and other expenses that we would not incur as a foreign private issuer.
• Because we are a foreign private issuer and are exempt from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.
• We are an emerging growth company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, this will make it more difficult to compare our performance with other public companies.
• Because we are an emerging growth company, we may not be subject to requirements that other public companies are subject to, which could affect investor confidence in us and our Class A Ordinary Shares.
• The laws of the Cayman Islands may not provide our shareholders with benefits comparable to those provided to shareholders of corporations incorporated in the United States.

Future Outlook

The company intends to use the proceeds from this offering for working capital and general corporate purposes, acquiring or investing in technologies, solutions or businesses that complement our business, and hiring experienced employees to improve our systems of internal control and compliance with U.S. GAAP and the Sarbanes-Oxley Act of 2002.

Industry Context

The company operates in the online marketing solution industry in China, with a focus on the healthcare sector. The industry is rapidly evolving and subject to regulatory changes.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• The document mentions that the company competes with other online marketing solution providers in China, but does not provide specific details about their performance or market share.
• The document mentions that the company's growth has benefited from the increase of news feed ads in the online marketing industry in China, but does not provide specific data about the growth rate of this segment compared to the overall industry.

Stakeholder Impact

• Shareholders face potential dilution and risks associated with the company's operations in China.
• Employees may be affected by changes in the company's business or regulatory environment.
• Customers may benefit from the company's efforts to improve its services and expand its market share.
• Suppliers may be affected by changes in the company's relationships with media platforms.

Next Steps

• The company will submit its filing application to the CSRC within three working days after the completion of this offering.
• The underwriters are expected to deliver such securities against payment in U.S. dollars in New York, New York on or about September 20, 2024.

Key Dates

Keywords

Haoxi Health Technology, unit offering, Class A Ordinary Shares, warrants, CSRC, China, regulatory risks, financial metrics, emerging growth company, controlled company, PCAOB, HFCA Act, Overseas Listing Trial Measures